<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684736</url>
  </required_header>
  <id_info>
    <org_study_id>TSK Sepsis</org_study_id>
    <nct_id>NCT00684736</nct_id>
  </id_info>
  <brief_title>Tryptophan, Serotonin and Kynurenine in Septic Shock</brief_title>
  <acronym>TSK</acronym>
  <official_title>Tryptophan, Serotonin and Kynurenine in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a major cause of mortality and morbidity worldwide. Serotonin (5-HT) is
      released by activated platelets into the circulation, and is mediator of endothelial
      dysfunction. 5-HT metabolism is known in immune system via specific 5-HT receptor, also in
      effects on the peripheral nervous system. Kinetic of 5-HT, tryptophan, kynurenine, MAO
      activity and IDO activity in human septic shock was never investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors</measure>
    <time_frame>Day-1, Day-2, Day-3, Day-7 and Day-14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Shock, Septic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were 18 years of age or older and had been hospitalized in our ICU were
        prospectively enrolled in the study if they met all eligibility criteria. Inclusion
        criteria were clinical evidence of infection, evidence of a systemic response to infection,
        and the onset of shock within the previous 3 hours.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above or equal to 18 years

          -  Strong presumption clinical sepsis

          -  Need for mechanical ventilation

          -  Body temperature above 38°C or below 36°C

          -  Heart rate above 90 bpm

          -  Systolic blood pressure of &lt;90mm Hg despite adequate fluid replacement or a need for
             vasopressors less than 3 hours

          -  Presence of at least one of the following criteria:

               -  Ratio of arterial oxygen tension over inspired fraction of oxygen of less than
                  300 mm Hg

               -  Urinary output below 0.5 mL per kg of bodyweight per h or below 30 mL/h (for at
                  least 1 h)

               -  Arterial lactate concentration above 2 mmol/L

          -  Consent signed

        Exclusion Criteria:

          -  Age below 18 years

          -  Pregnancy

          -  Underlying disease with a poor prognosis, a life expectancy of less than 24 hours

          -  Depression or melancholy

          -  Neuropsychiatric diseases: Seizure, manic psychosis, Migraine, or Drug addiction

          -  Neuroendocrine tumors

          -  Obstructive cardiomyopathy or acute myocardial ischaemia

          -  Pulmonary embolism

          -  Advanced stage cancer, malignant haemopathy, or AIDS with a decision to withhold or
             withdraw aggressive therapies

          -  Inclusion in another clinical trial

          -  Patient who receive before inclusion one of the following treatment known to modify
             serotonin level: almotriptan, amitriptyline, amoxapine, citalopram, clomipramine,
             clozapine, desipramine, dihydroergotamine, dolasetron, dosulepin, doxepin, eletriptan,
             ergotamine, flunarizine, fluoxetine, fluvoxamine, granisetron, imipramine, indoramin,
             interferon Alfa, interferon alfacon-1, interferon beta, iproniazid, maprotiline,
             methysergide, mianserin, Milnacipran, mirtazapine, moclobemide, naratriptan,
             olanzapine, ondansetron, oxetorone, paroxetine, pizotifen, risperidone, sertraline,
             sumatriptan, tianeptine, trimipramine, tropisetron, venlafaxine,viloxazine,
             zolmitriptan.

          -  No consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Bédos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odile Spreux-Varoquaux, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthieu Henry-Lagarrigue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Versailles - André Mignot Hospital</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Henry-Lagarrigue Matthieu/MD</name_title>
    <organization>Intensive Care Unit</organization>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>shock</keyword>
  <keyword>serotonin</keyword>
  <keyword>kynurenine</keyword>
  <keyword>tryptophan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

